Monday, May 21, 2018 6:01:53 PM
"are current liabilities not subtracted from cash and cash equivalents?"
Eventually they are. Current liabilities are PAID out of cash and not subtracted until that happens. So "as of March 31, 2018" the company had $10.6M in cash and owed a total of $2.3M of which $1.7M was due to TheraCour. Same thing said another way would be to say that the company has $8.3M in cash more than they currently owe.
"why specifically mention the $602K and the $1,689K here at all?"
"why these bits of information and not others from their balance sheet?"
Same answer to both and it's in the section Heading, which is "Liquidity and Capital Reserves".
The sole purpose of the section is for management to discuss the adequacy of their cash to meet the company's expected needs. Other balance sheet items are discussed in other sections or not at all but these bits are right where they belong.
Hope that was clear enough. If not let me know. Thank you for not asking me to explain the derivative liability. It's a BIG number but it doesn't normally require an outlay of cash at any point. It comes out of previous issuances of options and/or warrants and the effect that share price changes in the market and new issuances have on their original pricing and that's all I'm sayin' about it :o)
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM